TY - JOUR T1 - De-labeling severe asthma diagnosis: the challenge of DIPNECH JF - ERJ Open Research JO - erjor DO - 10.1183/23120541.00485-2021 SP - 00485-2021 AU - Caroline Hurabielle AU - Camille Taillé AU - Grégoire Prévot AU - Maud Russier AU - Alain Didier AU - Pierre-Olivier Girodet AU - Magali Colombat AU - Julien Mazières AU - Laurent Guilleminault Y1 - 2021/01/01 UR - http://openres.ersjournals.com/content/early/2021/12/16/23120541.00485-2021.abstract N2 - Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) is a rare pulmonary disease characterised by neuroendocrine cell hyperplasia within the bronchial epithelium [1]. The clinical presentation is characterised by non-specific respiratory symptoms such as chronic cough, dyspnea and bronchospasm. Given the rarity of the disease and the low specificity of symptoms, the diagnosis of DIPNECH is challenging and the time between symptom onset and diagnosis is long [1]. DIPNECH comprises a generalised proliferation of scattered neuroendocrine cells, small nodules (neuroendocrine bodies) or a linear proliferation of pulmonary neuroendocrine cells. It has been suggested that DIPNECH may mimick [2] or precede asthma [3]. The role of products of neuroendocrine cells, such as substance P, which contribute to eosinophil migration, has been suggested to explain asthma symptoms in DIPNECH [3]. However, the characteristics of patients with DIPNECH who have symptoms suggestive of asthma have never been described. The aim of our study was to determine whether patients diagnosed with DIPNECH and initially referred for severe asthma management had specific characteristics.FootnotesThis manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.Conflict of interest: Caroline Hurabielle has nothing to disclose.Conflict of interest: Dr. Taillé reports grants, personal fees and non-financial support from GSK, grants and personal fees from Sanofi, grants, personal fees and non-financial support from AstraZeneca, personal fees from Novartis, personal fees from Stallergenes, outside the submitted work; and Participation on a Data Safety Monitoring Board or Advisory Board for AstraZeneca, GSK, Sanofi and Novartis.Conflict of interest: Grégoire Prévot has nothing to disclose.Conflict of interest: Maud Russier has nothing to disclose.Conflict of interest: Alain Didier has nothing to disclose.Conflict of interest: Pierre-Olivier Girodet has nothing to disclose.Conflict of interest: Magali Colombat has nothing to disclose.Conflict of interest: Julien Mazières has nothing to disclose.Conflict of interest: Laurent Guilleminault has nothing to disclose. ER -